Recent Posts
Social•Feb 20, 2026
Lymphopenia Reversal Won’t Secure Anktiva FDA Approval
Reversal of lymphopenia is not an acceptable endpoint for Anktiva FDA approval. $IBRX could file but if it did, the application would be rejected.
By Adam Feuerstein
Social•Feb 19, 2026
Gossamer Lung Trial and ProMis Alzheimer Therapy Spotlight
This week's Biotech Scorecard newsletter: -- What to expect from $GOSS Gossamer Bio’s late-stage lung disease study -- A better, safer Alzheimer’s treatment? ProMis $PMN takes its shot https://t.co/YaA8kvUR4Z
By Adam Feuerstein
Social•Feb 19, 2026
INSM Projects 2026 Brinsupri Sales Minimum $1B
$INSM guides to 2026 Brinsupri sales of "at least $1B" in line with consensus. https://t.co/o7JhPKU3m1
By Adam Feuerstein
Social•Feb 18, 2026
FDA's Moderna U‑turn Highlights Agency Chaos
The FDA’s Moderna $MRNA pirouette is one more sign of chaos at the agency https://t.co/zThJqhT2BS via @matthewherper
By Adam Feuerstein
Social•Feb 18, 2026
Moderna's Flu Vaccine Review Set for August 5
$MRNA says FDA will now review its flu vaccine. PDUFA date is Aug. 5. https://t.co/npZzeEa5nk
By Adam Feuerstein
Social•Feb 15, 2026
Saudi‑US Biotech Tie Is Just a Pay‑for‑promotion Scheme
This is not a Saudi-USA Biotech Alliance, it’s a Saudi @DrPatrick $IBRX “you pay we pay” marketing campaign. Anktiva is stalled in the US because he can’t generate the clinical data to move the drug forward, so he goes to...
By Adam Feuerstein
Social•Feb 13, 2026
FDA Rejects IRON Disc’s Rare Disease Therapy, CNPV Stumbles
FDA rejects rare disease therapy from $IRON Disc Medicine, early recipient of commissioner’s voucher CNPV program falters out of the starting gate... https://t.co/w4ptB2ecRS via @LizzyLaw_ and me
By Adam Feuerstein
Social•Feb 12, 2026
FDA Approved Pembrolizumab Using Single‑Arm Trials Across Tumors
It would be highly instructive to read the pembrolizumab paper highlighted by @DrPatrick. Of course, he doesn't expect anyone to do that. This is what it says IN THE FIRST PARAGRAPH: The FDA approved pembrolizumab on May 23, 2017, for...
By Adam Feuerstein
Social•Feb 12, 2026
FDA’s Prasad‑Era: Rules Shift, Rare‑Disease Drugs Stalled
This week's Biotech Scorecard newsletter: The old Vinay Prasad never left. He just changed jobs Submissions to the FDA are handled by teams of reviewers, of course. But when I look across all of these recent cases, I see a...
By Adam Feuerstein
Social•Jan 20, 2026
Corvus Pill Yields 75% EASI‑75 Response in Eczema Trial
$CRVS Corvus pill shows promise in early-stage eczema trial 75% of participants treated with soquelitinib achieved EASI 75 after 8 weeks compared to 20% of placebo participants offered a placebo. https://t.co/XlOmX0GUZf
By Adam Feuerstein
Social•Jan 19, 2026
IBRX Quilt-3.092 Study Mandates Pre‑
The $IBRX Quilt-3.092 CAR-NK study also requires patients to undergo lymphodepleting chemotherapy prior to cell therapy infusion. https://t.co/fPMR7Jhwht
By Adam Feuerstein